Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2014, Article ID 980301, 10 pages
http://dx.doi.org/10.1155/2014/980301
Review Article

Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

1National Research Center, Tahrir Street, Cairo, Egypt
2Adult HSCT Program, Ain Shams University Hospitals, P.O. Box 1156, Cairo, Egypt
3Adult HSCT Program, Oncology Center, King Faisal Specialist Hospital & Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia
4Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Center, P.O. BOX 3354, Riyadh 11211, Saudi Arabia

Received 17 July 2014; Revised 22 September 2014; Accepted 23 September 2014; Published 27 October 2014

Academic Editor: Diego Cantarovich

Copyright © 2014 Amr Nassar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. R. Appelbaum, “Haematopoietic cell transplantation as immunotherapy,” Nature, vol. 411, no. 6835, pp. 385–389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Jacobsohn, M. Arora, J. P. Klein et al., “Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease,” Blood, vol. 118, no. 16, pp. 4472–4479, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Maeda, “Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses,” International Journal of Hematology, vol. 98, no. 3, pp. 293–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Jagasia, M. Arora, M. E. D. Flowers et al., “Risk factors for acute GVHD and survival after hematopoietic cell transplantation,” Blood, vol. 119, no. 1, pp. 296–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Arora, J. P. Klein, D. J. Weisdorf et al., “Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis,” Blood, vol. 117, no. 24, pp. 6714–6720, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Veltri, M. Regier, A. Cumpston et al., “Incidence and pattern of graft-versus-host disease in patients undergoing allogeneic transplantation after nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin,” Bone Marrow Research, vol. 2013, Article ID 414959, 8 pages, 2013. View at Publisher · View at Google Scholar
  7. O. Ringdén, M. M. Horowitz, P. Sondel et al., “Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?” Blood, vol. 81, no. 4, pp. 1094–1101, 1993. View at Google Scholar · View at Scopus
  8. R. Reshef, “Prevention of graft-versus-host disease,” Clinical Advances in Hematology and Oncology, vol. 10, no. 10, pp. 663–665, 2012. View at Google Scholar
  9. N. Askenasy, K. Mizrahi, S. Ash, E. M. Askenasy, I. Yaniv, and J. Stein, “Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity,” Biology of Blood and Marrow Transplantation, vol. 19, no. 2, pp. 185–195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Matějková, V. Foltánkov Á, and I. Burešov Á, “Selective depletion of alloreactive donor T cells leads to elimination of graft-versus-host reactivity and stimulates graft-versus-leukaemia/myeloma effect,” Folia Biologica, vol. 59, no. 4, pp. 146–153, 2013. View at Google Scholar · View at Scopus
  11. S. Parmar, X. Liu, S. S. Tung et al., “Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease,” Cytotherapy, vol. 16, no. 1, pp. 90–100, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Gao, F. Liu, L. Tan, T. Liu, Z. Chen, and C. Shi, “The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease,” Biomaterials, vol. 35, no. 11, pp. 3582–3588, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Safinia, J. Leech, M. Hernandez-Fuentes, R. Lechler, and G. Lombardi, “Promoting transplantation tolerance; adoptive regulatory T cell therapy,” Clinical and Experimental Immunology, vol. 172, no. 2, pp. 158–168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Kanda, K. Izutsu, H. Hirai et al., “Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate,” Leukemia, vol. 18, no. 5, pp. 1013–1019, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Storb, J. H. Antin, and C. Cutler, “Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?” Biology of Blood and Marrow Transplantation, vol. 16, no. 1, pp. S18–S27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Perez-Simón, R. Martino, R. Parody et al., “The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate,” Haematologica, vol. 98, no. 4, pp. 526–532, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Johnston, M. Florek, R. Armstrong et al., “Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation,” Bone Marrow Transplantation, vol. 47, no. 4, pp. 581–588, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. R. Couriel, R. M. Saliba, S. Giralt et al., “Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation,” Biology of Blood and Marrow Transplantation, vol. 10, no. 3, pp. 178–185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Reshef, S. M. Luger, E. O. Hexner et al., “Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease,” The New England Journal of Medicine, vol. 367, no. 2, pp. 135–145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. H. Antin, D. Weisdorf, D. Neuberg et al., “Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation,” Blood, vol. 100, no. 10, pp. 3479–3483, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Hamadani, C. C. Hofmeister, B. Jansak et al., “Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 14, no. 7, pp. 783–789, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H. J. Deeg, “How I treat refractory acute GVHD,” Blood, vol. 109, no. 10, pp. 4119–4126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. P. J. Martin, J. D. Rizzo, J. R. Wingard et al., “First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation,” Biology of Blood and Marrow Transplantation, vol. 18, no. 8, pp. 1150–1163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Weisdorf, R. Haake, B. Blazar et al., “Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome,” Blood, vol. 75, no. 4, pp. 1024–1030, 1990. View at Google Scholar · View at Scopus
  25. M. T. van Lint, C. Uderzo, A. Locasciulli et al., “Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation,” Blood, vol. 92, no. 7, pp. 2288–2293, 1998. View at Google Scholar · View at Scopus
  26. J. Roy, P. B. McGlave, A. H. Filipovich et al., “Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy,” Bone Marrow Transplantation, vol. 10, no. 1, pp. 77–82, 1992. View at Google Scholar · View at Scopus
  27. L. Cragg, B. R. Blazar, T. Defor et al., “A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 6, no. 4, pp. 441–447, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. J. E. Levine, S. Paczesny, S. Mineishi et al., “Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease,” Blood, vol. 111, no. 4, pp. 2470–2475, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. D. R. Couriel, R. Saliba, M. de Lima et al., “A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 15, no. 12, pp. 1555–1562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. T. van Lint, G. Milone, S. Leotta et al., “Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin,” Blood, vol. 107, no. 10, pp. 4177–4181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. P. J. Martin, D. Weisdorf, D. Przepiorka et al., “Design of Clinical Trials Working Group. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report,” Biology of Blood and Marrow Transplant, vol. 12, no. 5, pp. 491–505, 2006. View at Publisher · View at Google Scholar
  32. A. Beilhaek, S. Schulz, J. Baker et al., “Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs,” Blood, vol. 111, no. 5, pp. 2919–2928, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Johnston, J. E. Gudjonsson, H. Sigmundsdottir, B. Runar Ludviksson, and H. Valdimarsson, “The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules,” Clinical Immunology, vol. 114, no. 2, pp. 154–163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Vettenranta, L. Hovi, K. Parto, and U. M. Saarinen-Pihkala, “Very low-dose methotrexate in the treatment of GVHD in children,” Bone Marrow Transplantation, vol. 20, no. 1, pp. 75–77, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Giaccone, P. Martin, P. Carpenter et al., “Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease,” Bone Marrow Transplantation, vol. 36, no. 4, pp. 337–341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. X.-J. Huang, Q. Jiang, H. Chen et al., “Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 36, no. 4, pp. 343–348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. H. de Lavallade, M. Mohty, C. Faucher, S. Fürst, J. El-Cheikh, and D. Blaise, “Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation,” Haematologica, vol. 91, no. 10, pp. 1438–1440, 2006. View at Google Scholar · View at Scopus
  38. J. Inagaki, Y. Nagatoshi, M. Hatano, N. Isomura, M. Sakiyama, and J. Okamura, “Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children,” Bone Marrow Transplantation, vol. 41, no. 6, pp. 571–577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Wang, L.-P. Xu, D.-H. Liu et al., “First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate,” Biology of Blood and Marrow Transplantation, vol. 15, no. 4, pp. 505–511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Wang, L. P. Xu, K. Y. Liu et al., “Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility,” Bone Marrow Transplantation, vol. 46, no. 6, pp. 892–898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Inagaki, R. Fukano, Y. Kodama, M. Nishimura, M. Shimokawa, and J. Okamura, “Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation,” Annals of Hematology, vol. 93, no. 4, pp. 645–651, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Trotti, A. D. Colevas, A. Setser et al., “CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment,” Seminars in Radiation Oncology, vol. 13, no. 3, pp. 176–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Devine, R. B. Geller, L. B. Lin et al., “The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis,” Biology of Blood and Marrow Transplantation, vol. 3, no. 1, pp. 25–33, 1997. View at Google Scholar · View at Scopus
  44. R. A. Nash, L. A. Piñeiro, R. Storb et al., “FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors,” Blood, vol. 88, no. 9, pp. 3634–3641, 1996. View at Google Scholar · View at Scopus
  45. A. O'Meara, B. Headon, and D. J. Reen, “Effect of methotrexate on the immune response in children with acute lymphatic leukaemia,” Immunopharmacology, vol. 9, no. 1, pp. 33–38, 1985. View at Publisher · View at Google Scholar · View at Scopus